tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GANX Stock Latest News

Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
RatingsOptimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
7d ago
GANX
Gain Therapeutics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Gain Therapeutics Reports 2024 Financial Results and Progress
7d ago
GANX
Gain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
PremiumThe Fly
Gain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
8d ago
GANX
Gain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
PremiumThe Fly
Gain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
8d ago
GANX
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
PremiumRatings
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
16d ago
GANX
GANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsGANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
17d ago
GANX
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
Premium
Ratings
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
18d ago
GANX
Gain Therapeutics doses first participant in Phase 1b trial of GT-02287
Premium
The Fly
Gain Therapeutics doses first participant in Phase 1b trial of GT-02287
21d ago
GANX
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
PremiumThe Fly
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
28d ago
W
AL
Gain Therapeutics initiated with an Outperform at Scotiabank
PremiumThe Fly
Gain Therapeutics initiated with an Outperform at Scotiabank
28d ago
GANX
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
PremiumCompany Announcements
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
2M ago
8K
GANX
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
PremiumThe Fly
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
2M ago
GANX
Gain Therapeutics announces formation of clinical advisory board
PremiumThe FlyGain Therapeutics announces formation of clinical advisory board
3M ago
GANX
Gain Therapeutics Appoints New CEO Amidst Clinical Progress
Premium
Company Announcements
Gain Therapeutics Appoints New CEO Amidst Clinical Progress
3M ago
8K
GANX
Gain Therapeutics appoints Mack as CEO, Director
Premium
The Fly
Gain Therapeutics appoints Mack as CEO, Director
3M ago
GANX
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM
PremiumThe Fly
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM
3M ago
GANX
Gain Therapeutics Advances GT-02287 into Phase 1b Trial
PremiumCompany Announcements
Gain Therapeutics Advances GT-02287 into Phase 1b Trial
3M ago
8K
GANX
Gain Therapeutics initiates Phase 1b trial of GT-02287
PremiumThe Fly
Gain Therapeutics initiates Phase 1b trial of GT-02287
3M ago
GANX
Gain initiated with Buy on Parkison’s potential at Roth MKM
PremiumThe Fly
Gain initiated with Buy on Parkison’s potential at Roth MKM
4M ago
GANX
Gain Therapeutics initiated with a Buy at Roth MKM
PremiumThe FlyGain Therapeutics initiated with a Buy at Roth MKM
4M ago
GANX
Gain Therapeutics Advances Parkinson’s Therapy Development
Premium
Company Announcements
Gain Therapeutics Advances Parkinson’s Therapy Development
5M ago
GANX
Closing Bell Movers: Applied Materials down 6% after earnings, guidance
Premium
The Fly
Closing Bell Movers: Applied Materials down 6% after earnings, guidance
5M ago
DPZ
INO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >